Company news

Matinas BioPharma Holdings, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

September 4, 2026

Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals

July 13, 2026

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance

June 26, 2026

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

April 3, 2026

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

March 11, 2025

Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

February 13, 2025

Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair

February 7, 2025

Matinas BioPharma Receives NYSE Noncompliance Notice

January 10, 2025

Current Report Form 8 K

November 27, 2024

Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)

November 13, 2024

Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction Form 8 K

October 31, 2024

Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update

August 14, 2024

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024

August 7, 2024

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program

June 24, 2024

New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024

May 16, 2024

Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update

May 9, 2024

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024

May 2, 2024

Matinas BioPharma Prices $10 Million Registered Direct Offering

April 3, 2024

Calls

The 5 newest of 6 calls. Every call is listed under its year.

Decks

The 5 newest of 28 decks. Every deck is listed under its year.